Skip to main content
. 2018 Jul 19;9:1650. doi: 10.3389/fimmu.2018.01650

Figure 5.

Figure 5

Figure 5

Administration of TLR-3L reverts the M2 phenotype of tumor-associated macrophages to M1 subtype. TLR3-L was administered in tumor-bearing mice. After 21 days, cells were isolated from the excised tumors and tumor-associated macrophages (TAMs) were assessed by flow cytometry for the expression of (A) CD80; (B) CD86; (C) TIM-3; and (D) MHC-II. The bar graphs expressed as mean ± SD represents the percentage change in the phenotypic markers on the F4/80+ positive cells (lower panel). The data shown are representative of two independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001).